David P. Douglass

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor

UAMS

Peds Pediatrics, College of Medicine

3 h-index 12 pubs 22 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

David P. Douglass studies pediatric cancers, with a focus on sarcomas and neuroblastoma. His research investigates novel therapeutic strategies, including the development of prognostic signatures and the evaluation of new agents. Douglass has published work on the role of pharmacotherapeutic agents in desmoid tumors and the clinical features of low-grade non-rhabdomyosarcoma soft tissue sarcomas. He has also explored molecular mechanisms in fusion-positive rhabdomyosarcoma and identified potential therapeutic targets, such as CDK9, for neuroblastoma and rhabdomyosarcoma. His collaborators include Kimo C. Stine, Varsha G. Desai, Vikrant Vijay, and James C. Fuscoe.

Metrics

h-index: 3
Publications: 12
Citations: 22

Positions

Associate Professor 2025–present

University of Arkansas for Medical Sciences Peds Pediatrics, College of Medicine Institutional directory
Assistant Professor 2019–2025

University of Arkansas for Medical Sciences Department of Pediatrics/Hematology-Oncology Section ORCID

Selected Publications

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)

Cardiovascular Toxicology DOI OpenAlex
Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma (2025)

Scientific Reports 1 citation DOI OpenAlex
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)

Cardiovascular Toxicology DOI OpenAlex
Clinical features and outcomes of young patients with low‐grade non‐rhabdomyosarcoma soft tissue sarcomas treated with a risk‐based strategy: A report from Children's Oncology Group study ARST0332 (2024)

Pediatric Blood & Cancer 4 citations DOI OpenAlex
Development and validation of a 21-gene prognostic signature in neuroblastoma (2023)

Scientific Reports 6 citations DOI OpenAlex
Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children (2023)

Cancer Research 1 citation DOI OpenAlex
Neonatal osteoblastic tumor with a novel PTBP1::FOSB fusion (2023)

Genes Chromosomes and Cancer 1 citation DOI OpenAlex
The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors (2022)

Pediatric Drugs 5 citations DOI OpenAlex
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance (2021)

Journal of Pediatric Hematology/Oncology 1 citation DOI OpenAlex
A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME - RESOLVING A VARIANT OF UNCERTAIN SIGNIFICANCE (2020)

DOI OpenAlex
Primary superficial Ewing sarcoma: A unique entity? A case report including novel findings of ELF3 and TNFRSF14 copy number loss (2020)

Journal of Cutaneous Pathology 7 citations DOI OpenAlex